# Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

> **NCT02419755** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 12 (actual)

## Conditions studied

- Mixed Lineage Acute Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Vorinostat
- **DRUG:** Mitoxantrone
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Hydrocortisone
- **DRUG:** Peg-L-Asparaginase
- **DRUG:** Erwinia L-Asparaginase
- **DRUG:** Dexamethasone
- **DRUG:** Mercaptopurine
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02419755
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-14
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Accrual goals were no longer feasible based on restrictions imposed by the DSMB.
- **Last updated:** 2018-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419755, "Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02419755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*